Terms: = Gastric cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
48 results:
1. ezh2 as a potential therapeutic target for gastrointestinal cancers.
Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the Potential Mechanism of Action of Ursolic Acid against gastric cancer and COVID-19 using Network Pharmacology and Bioinformatics Analysis.
Liu Z; Huang H; Yu Y; Jia Y; Li L; Shi X; Wang F
Curr Pharm Des; 2023; 29(16):1274-1292. PubMed ID: 37218202
[TBL] [Abstract] [Full Text] [Related]
3. Identification and validation of a novel prognostic circadian rhythm-related gene signature for stomach adenocarcinoma.
Qian L; Ding X; Fan X; Li S; Qiao Y; Zhang X; Li J
Chronobiol Int; 2023 Jun; 40(6):744-758. PubMed ID: 37122167
[TBL] [Abstract] [Full Text] [Related]
4. Multiplexed immunofluorescence analysis of CAF-markers, ezh2 and FOXM1 in gastric tissue: associations with clinicopathological parameters and clinical outcomes.
Sun H; Wang X; Zhang X; Wang X; Tan C; Weng W; Zhang M; Ni S; Wang L; Huang D; Xu M; Sheng W
BMC Cancer; 2022 Nov; 22(1):1188. PubMed ID: 36401232
[TBL] [Abstract] [Full Text] [Related]
5. OCT4-mediated transcription confers oncogenic advantage for a subset of gastric tumors with poor clinical outcome.
Pandian J; Panneerpandian P; Sekar BT; Selvarasu K; Ganesan K
Funct Integr Genomics; 2022 Dec; 22(6):1345-1360. PubMed ID: 35987846
[TBL] [Abstract] [Full Text] [Related]
6. Poorly Cohesive gastric cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively.
Bencivenga M; Simbolo M; Ciaparrone C; Vicentini C; Torroni L; Piredda ML; Sacco M; Alloggio M; Castelli C; Tomezzoli A; Scarpa A; De Manzoni G
Ann Surg; 2022 Nov; 276(5):822-829. PubMed ID: 35930005
[TBL] [Abstract] [Full Text] [Related]
7. Long non-coding RNA ZNF674-AS1 antagonizes oxaliplatin resistance of gastric cancer via regulating ezh2-mediated methylation of CHST7.
Ye K; Wang Y
Aging (Albany NY); 2022 Jul; 14(13):5523-5536. PubMed ID: 35802620
[TBL] [Abstract] [Full Text] [Related]
8. miR-137 Modulates Human gastric cancer Cell Proliferation, Apoptosis, and Migration by Targeting ezh2.
Weng XQ; Wang W
Crit Rev Eukaryot Gene Expr; 2022; 32(4):31-40. PubMed ID: 35695663
[TBL] [Abstract] [Full Text] [Related]
9. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
10. ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with ezh2 and regulating miR-200c-3p/Notch1 axis.
Mao X; Ji T; Liu A; Weng Y
Cell Death Dis; 2021 Oct; 12(11):957. PubMed ID: 34663788
[TBL] [Abstract] [Full Text] [Related]
11. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus.
Liu HT; Zou YX; Zhu WJ; Sen-Liu ; Zhang GH; Ma RR; Guo XY; Gao P
Cell Death Differ; 2022 Mar; 29(3):627-641. PubMed ID: 34608273
[TBL] [Abstract] [Full Text] [Related]
12. The Role of Tumor-related LncRNA PART1 in cancer.
Chen J; Meng E; Lin Y; Shen Y; Hu C; Zhou G; Yuan C
Curr Pharm Des; 2021; 27(40):4152-4159. PubMed ID: 34225608
[TBL] [Abstract] [Full Text] [Related]
13. LINC00152 mediates CD8
Ou J; Lei P; Yang Z; Yang M; Luo L; Mo H; Luo G; He J
J Mol Histol; 2021 Jun; 52(3):611-620. PubMed ID: 33709190
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression.
Chen S; Huang L; Li G; Qiu F; Wang Y; Yang C; Pan J; Wu Z; Chen J; Tian Y
Clin Epigenetics; 2020 Nov; 12(1):168. PubMed ID: 33160411
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of ezh2 and activation of ERRĪ³ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
[TBL] [Abstract] [Full Text] [Related]
16. MicroRNA-625-3p inhibits gastric cancer metastasis through modulating ezh2.
Li Y; Zhou HC; Zhang Y; Huang H
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1177-1185. PubMed ID: 32096165
[TBL] [Abstract] [Full Text] [Related]
17. Upregulation of nuclear-enriched abundant transcript 1 confers oxaliplatin resistance to gastric cancer.
Li Y; Peng C; Fang C; Huang K
Cell Biol Int; 2020 Feb; 44(2):446-455. PubMed ID: 31617275
[TBL] [Abstract] [Full Text] [Related]
18. HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting ezh2.
Ye Y; Yang S; Han Y; Sun J; Xv L; Wu L; Ming L
Open Biol; 2019 Sep; 9(9):190068. PubMed ID: 31551012
[TBL] [Abstract] [Full Text] [Related]
19. Long non-coding RNA SNHG3 promotes progression of gastric cancer by regulating neighboring MED18 gene methylation.
Xuan Y; Wang Y
Cell Death Dis; 2019 Sep; 10(10):694. PubMed ID: 31534128
[TBL] [Abstract] [Full Text] [Related]
20. ezh2 promotes gastric cancer cells proliferation by repressing p21 expression.
Xu J; Wang Z; Lu W; Jiang H; Lu J; Qiu J; Ye G
Pathol Res Pract; 2019 Jun; 215(6):152374. PubMed ID: 30952377
[TBL] [Abstract] [Full Text] [Related]
[Next]
